TY - JOUR
T1 - Therapeutic mRNA delivery to leukocytes
AU - Granot-Matok, Yasmin
AU - Kon, Edo
AU - Dammes, Niels
AU - Mechtinger, Gilad
AU - Peer, Dan
N1 - Funding Information:
This work was supported in part by grants from the Dotan Hemato-oncology Center at Tel Aviv University, and by the ERC grant LeukoTheranostics (number 647410 ) awarded to D.P.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/7/10
Y1 - 2019/7/10
N2 - In the past few years mRNA molecules have become an attractive class of new drugs with numerous opportunities. mRNA therapeutics holds great potential for the treatment of a variety of diseases and is an emerging field both in academia and in the pharma industry. Among the various mRNA-based therapeutic approaches, immunotherapy is one of the pioneering and most advanced therapy to date. Immune cells manipulation using mRNA is commonly used for vaccination purposes, but its potential is much broader. In this review, we discuss the promise of mRNA delivery to leukocytes. We aim to provide an overview of the main progress in this field, as well as the challenges in expanding the scope of mRNA therapy for different therapeutic applications. We also discuss the main technological developments for overcoming mRNA therapy limitations, including mRNA rational design and delivery platforms.
AB - In the past few years mRNA molecules have become an attractive class of new drugs with numerous opportunities. mRNA therapeutics holds great potential for the treatment of a variety of diseases and is an emerging field both in academia and in the pharma industry. Among the various mRNA-based therapeutic approaches, immunotherapy is one of the pioneering and most advanced therapy to date. Immune cells manipulation using mRNA is commonly used for vaccination purposes, but its potential is much broader. In this review, we discuss the promise of mRNA delivery to leukocytes. We aim to provide an overview of the main progress in this field, as well as the challenges in expanding the scope of mRNA therapy for different therapeutic applications. We also discuss the main technological developments for overcoming mRNA therapy limitations, including mRNA rational design and delivery platforms.
UR - http://www.scopus.com/inward/record.url?scp=85066268885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066268885&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2019.05.032
DO - 10.1016/j.jconrel.2019.05.032
M3 - Review article
C2 - 31121277
AN - SCOPUS:85066268885
SN - 0168-3659
VL - 305
SP - 165
EP - 175
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -